Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 19 | 2025 | 1408 | 5.290 |
Why?
|
| Community Health Workers | 6 | 2025 | 75 | 3.170 |
Why?
|
| Telemedicine | 7 | 2025 | 495 | 2.990 |
Why?
|
| Hypoglycemic Agents | 7 | 2025 | 482 | 2.340 |
Why?
|
| Diabetes Mellitus | 7 | 2025 | 921 | 2.180 |
Why?
|
| Cardiovascular Diseases | 11 | 2025 | 2092 | 0.930 |
Why?
|
| Metformin | 3 | 2024 | 166 | 0.800 |
Why?
|
| Self-Management | 1 | 2024 | 108 | 0.770 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 459 | 0.680 |
Why?
|
| Diabetic Foot | 1 | 2022 | 168 | 0.630 |
Why?
|
| Patient Selection | 1 | 2023 | 737 | 0.630 |
Why?
|
| House Calls | 1 | 2019 | 38 | 0.590 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 142 | 0.580 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 92 | 0.560 |
Why?
|
| Psychotherapy, Group | 1 | 2017 | 59 | 0.530 |
Why?
|
| Poverty | 4 | 2023 | 446 | 0.520 |
Why?
|
| Veterans | 3 | 2022 | 1757 | 0.510 |
Why?
|
| Humans | 39 | 2025 | 132062 | 0.470 |
Why?
|
| Patient Care Team | 1 | 2017 | 571 | 0.400 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 896 | 0.380 |
Why?
|
| Sulfonylurea Compounds | 2 | 2024 | 20 | 0.370 |
Why?
|
| Cardiology | 4 | 2024 | 498 | 0.360 |
Why?
|
| Thiazolidinediones | 2 | 2024 | 81 | 0.360 |
Why?
|
| Adult | 11 | 2025 | 31568 | 0.330 |
Why?
|
| Quality of Life | 4 | 2024 | 2137 | 0.280 |
Why?
|
| Middle Aged | 10 | 2025 | 28964 | 0.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 743 | 0.240 |
Why?
|
| Aged | 8 | 2025 | 21406 | 0.240 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2025 | 40 | 0.240 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 1180 | 0.230 |
Why?
|
| Male | 13 | 2025 | 64922 | 0.220 |
Why?
|
| Female | 13 | 2025 | 70712 | 0.210 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 31 | 0.210 |
Why?
|
| Obesity | 4 | 2025 | 2391 | 0.210 |
Why?
|
| Community Health Centers | 1 | 2023 | 37 | 0.210 |
Why?
|
| Primary Prevention | 1 | 2024 | 178 | 0.200 |
Why?
|
| Depression | 2 | 2023 | 1333 | 0.190 |
Why?
|
| Feedback | 1 | 2023 | 164 | 0.190 |
Why?
|
| Publishing | 1 | 2024 | 106 | 0.190 |
Why?
|
| Health Education | 1 | 2024 | 234 | 0.180 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 482 | 0.180 |
Why?
|
| Rural Population | 1 | 2023 | 240 | 0.180 |
Why?
|
| Research Design | 2 | 2023 | 741 | 0.180 |
Why?
|
| Pediatric Obesity | 2 | 2017 | 415 | 0.170 |
Why?
|
| Anticholesteremic Agents | 1 | 2023 | 239 | 0.170 |
Why?
|
| Social Support | 1 | 2023 | 385 | 0.170 |
Why?
|
| Sleep Wake Disorders | 1 | 2023 | 197 | 0.170 |
Why?
|
| Lower Extremity | 1 | 2022 | 190 | 0.170 |
Why?
|
| Multimorbidity | 1 | 2020 | 23 | 0.160 |
Why?
|
| Goals | 1 | 2021 | 132 | 0.160 |
Why?
|
| Health Status Indicators | 1 | 2020 | 128 | 0.160 |
Why?
|
| Insulins | 1 | 2020 | 19 | 0.160 |
Why?
|
| Weight Reduction Programs | 1 | 2020 | 60 | 0.160 |
Why?
|
| Mentors | 1 | 2021 | 162 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 480 | 0.150 |
Why?
|
| Congresses as Topic | 3 | 2025 | 185 | 0.150 |
Why?
|
| Videoconferencing | 1 | 2019 | 22 | 0.150 |
Why?
|
| Telephone | 1 | 2019 | 123 | 0.150 |
Why?
|
| Medicaid | 1 | 2021 | 251 | 0.150 |
Why?
|
| Group Processes | 1 | 2019 | 51 | 0.150 |
Why?
|
| Behavior Therapy | 1 | 2021 | 269 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2019 | 367 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2019 | 206 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2020 | 283 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2020 | 698 | 0.140 |
Why?
|
| Body Mass Index | 3 | 2020 | 1694 | 0.130 |
Why?
|
| Anxiety | 1 | 2023 | 987 | 0.130 |
Why?
|
| Life Style | 4 | 2021 | 450 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1450 | 0.130 |
Why?
|
| Risk Factors | 4 | 2025 | 10941 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 648 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2017 | 792 | 0.120 |
Why?
|
| Seasons | 1 | 2017 | 327 | 0.120 |
Why?
|
| Weight Loss | 4 | 2021 | 515 | 0.120 |
Why?
|
| Child Behavior | 1 | 2017 | 236 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2021 | 1400 | 0.120 |
Why?
|
| Acculturation | 1 | 2015 | 63 | 0.120 |
Why?
|
| Body Weight | 2 | 2017 | 994 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2017 | 828 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 668 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2019 | 1123 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1436 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1183 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2023 | 5164 | 0.110 |
Why?
|
| Atherosclerosis | 1 | 2022 | 1010 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5409 | 0.090 |
Why?
|
| Overweight | 3 | 2021 | 383 | 0.090 |
Why?
|
| United States | 5 | 2025 | 11658 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 3990 | 0.080 |
Why?
|
| Texas | 1 | 2019 | 3629 | 0.080 |
Why?
|
| Global Health | 2 | 2025 | 643 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2020 | 13028 | 0.060 |
Why?
|
| Kenya | 1 | 2023 | 58 | 0.050 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2023 | 9 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 372 | 0.050 |
Why?
|
| Editorial Policies | 1 | 2024 | 50 | 0.050 |
Why?
|
| Proprotein Convertase 9 | 1 | 2023 | 81 | 0.050 |
Why?
|
| Writing | 1 | 2024 | 66 | 0.050 |
Why?
|
| American Heart Association | 1 | 2025 | 309 | 0.050 |
Why?
|
| Exercise | 2 | 2020 | 857 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2025 | 286 | 0.050 |
Why?
|
| Data Collection | 1 | 2023 | 390 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 74 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 50 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 136 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 778 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2023 | 7102 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 606 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2023 | 256 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2020 | 94 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 299 | 0.040 |
Why?
|
| Caloric Restriction | 1 | 2020 | 96 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1491 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2017 | 17419 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2021 | 328 | 0.030 |
Why?
|
| Glucose | 1 | 2022 | 878 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 172 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 791 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 1247 | 0.020 |
Why?
|
| Young Adult | 1 | 2023 | 9957 | 0.020 |
Why?
|
| Child | 2 | 2017 | 25789 | 0.020 |
Why?
|
| Adolescent | 1 | 2023 | 20562 | 0.010 |
Why?
|